Sunshine Selling And Marketing Expenses from 2010 to 2025

SBFMW Stock  USD 0.20  0.01  4.76%   
Sunshine Biopharma Selling And Marketing Expenses yearly trend continues to be fairly stable with very little volatility. Selling And Marketing Expenses is likely to outpace its year average in 2025. During the period from 2010 to 2025, Sunshine Biopharma Selling And Marketing Expenses regression line of quarterly data had mean square error of 14.4 B and geometric mean of  282,725. View All Fundamentals
 
Selling And Marketing Expenses  
First Reported
2010-12-31
Previous Quarter
844.4 K
Current Value
886.6 K
Quarterly Volatility
286.2 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 34.9 M or Total Operating Expenses of 15.8 M, as well as many indicators such as Price To Sales Ratio of 0.3, Dividend Yield of 0.0 or PTB Ratio of 0.34. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
  
Check out the analysis of Sunshine Biopharma Correlation against competitors.
For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

Latest Sunshine Biopharma's Selling And Marketing Expenses Growth Pattern

Below is the plot of the Selling And Marketing Expenses of Sunshine Biopharma Warrant over the last few years. It is Sunshine Biopharma's Selling And Marketing Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.
Selling And Marketing Expenses10 Years Trend
Slightly volatile
   Selling And Marketing Expenses   
       Timeline  

Sunshine Selling And Marketing Expenses Regression Statistics

Arithmetic Mean469,495
Geometric Mean282,725
Coefficient Of Variation60.97
Mean Deviation240,684
Median578,085
Standard Deviation286,232
Sample Variance81.9B
Range884.6K
R-Value0.91
Mean Square Error14.4B
R-Squared0.84
Slope54,959
Total Sum of Squares1.2T

Sunshine Selling And Marketing Expenses History

2025886.6 K
2024844.4 K
2023734.2 K
2015578.1 K
2011105 K
2010 2000.0

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors use historical fundamental indicators, such as Sunshine Biopharma's Selling And Marketing Expenses, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sunshine Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Selling And Marketing Expenses844.4 K886.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.